Serbia Pioglitazone Hydrochloride Tablets (14 tablets)

Approval Number: State Drug License H20070229 Dosage Form: Tablet Specification: 15mg (in C19H20N2O3S). Manufacturer: Yantai Zhengfang Pharmaceutical Co., Ltd Address: No.16, Qinhuaihe Road, Yantai Economic and Technological Development Zone Product Category: Chemical Drugs Approval Date: 2012-11-01 Drug Code: 86904250000011 Execution Standard: The Second Supplement to Chinese Pharmacopoeia, 2010 Edition

Category:

SerbiaPioglitazone Hydrochloride Tablets

Phone:86 0535-6105987

Inquire

Product Description

Pioglitazone Hydrochloride Tablets

（State Drug License No. 20070229）

Indications:

In patients with type 2 diabetes mellitus (non-insulin-dependent diabetes mellitus, NIDDM), pioglitazone hydrochloride may be used in combination with dietary control and physical activity to improve and control blood glucose. Pioglitazone hydrochloride may be used alone, or it may be combined with sulfonylurea, metformin, or insulin when dietary control, physical activity, and monotherapy do not provide satisfactory glycemic control.

Product Characteristics:
1、 National medical insurance class β drugs;
2, Directly attacking insulin resistance and protecting pancreatic β-cells;
3、 Long-lasting and stable glucose lowering;
4, Lowering fat, lowering blood pressure, protecting kidney;
5、 No need to adjust the dosage for renal impairment and elderly patients;
6, This product will not cause hypoglycemia when used alone.

SerbiaPioglitazone Hydrochloride Tablets (9 tablets)

SerbiaPioglitazone Hydrochloride Tablets (28 tablets)

: next page